Sort   by:  
 Page size 
MetabolomicsRBC Balanced Immuno-inflammatory Signatures Identify Advanced Breast Cancer Patients on CDK4/6 Inhibitors at Increased Risk of Progression and Death

Recent studies show red blood cell (RBC) plays an essential role in regulating immunity. Nevertheless, the association of immuno-inflammatory parameters, especially RBC balanced signatures, with survival outcomes and adverse events still require investigation for advanced breast cancer (ABC) pati...

2025-04-15 | MTBLS10792 | MetaboLights
MetabolomicsCDK4/6 inhibitor-mediated cell overgrowth triggers an osmotic stress response and chronic p38MAPK activation to promote long-term cell cycle arrest

Cell size and the cell cycle are intrinsically coupled and abnormal increases in cell size are associated with senescence and permanent cell cycle arrest. The mechanism by which overgrowth primes cells to withdraw from the cell cycle remains unknown. We investigate this here using CDK4/6 inhibito...

2025-10-24 | MTBLS5868 | MetaboLights
MetabolomicsCell overgrowth potentiates osmotic and replication stresses to promote p38/p53/p21-dependent senescence
Abnormal increases in cell size are associated with senescence and cell cycle exit. The mechanisms by which overgrowth primes cells to withdraw from the cell cycle remain unknown. We address this question using CDK4/6 inhibitors, which arrest cells in G0/G1 and are licensed to treat advanced HR+/HER...
2025-10-24 | MTBLS8698 | MetaboLights
TranscriptomicsExpression data from vehicle or PD-0332991 treated human T-ALL lines
Cyclin D3 is critical hematopoiesis and loss of cyclin D3 leads to resistance to transformation of bone marrow progenitors by Notch1-IC. We used a small molecule targeting cyclin D3:CDK4/6 activity to study whether its inhibition is an effective therapeutic strategy. We analyzed T-ALL lines in vitro...
ORGANISM(S): Homo sapiens 
2012-12-13 | E-GEOD-40635 | biostudies-arrayexpress
ProteomicsCDK4/6 inhibitor resistance in prostate cancer
CDK4/6 kinase inhibitors have shown great promise in clinical trials in various cancer types and have recently entered clinical trial for advanced prostate cancer. Although patients are expected to respond well to this class of drugs, development of resistance in some patients is anticipated. To pre...
ORGANISM(S): Homo sapiens (Human) 
2018-05-16 | PXD006561 | Pride
Palbociclib Lapc4 Ribociclib Cdk4/6 Prostate cancer Lncap 
TranscriptomicsExpression profile of BCR-ABL1-transformed, Cdk4 R24C, Cdk6 R31C cell lines
Cdk4 and Cdk6 are two related kinases that bind D-type cyclins and regulate cell cycle progression. Due to their relevance in cancer, Cdk4/6 inhibitors are currently in advanced clinical trials in multiple tumor types. Cdk4/6 are inhibited by INK4 proteins that exert tumor suppressing functions. To ...
ORGANISM(S): Mus musculus 
2014-11-04 | E-GEOD-59024 | biostudies-arrayexpress
ProteomicsProteomics comparison of protein changes in H1299 cell before and after resistance to cdk4/6 inhibitors
This is the raw proteomics data of H1299 cell before and after resistance to cdk4/6 inhibitors
ORGANISM(S): Homo Sapiens 
2023-05-15 | PXD042216 |
ProteomicsDistinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
CDK4/6 inhibitors (CDK4/6i) are effective in metastatic breast cancer, but they have been only modestly effective in most other tumor types. Here we show that tumors expressing low CDK6 rely on CDK4 function, and are exquisitely sensitive to CDK4/6i. In contrast, tumor cells expressing both CDK4 and...
ORGANISM(S): Homo sapiens (Human) 
2022-02-16 | PXD023137 | Pride
Cdk4/6 inhibitors and degraders Cdk6 complex Tumor 
ProteomicsCDK4/6 inhibitors induce repication stress to cause long-term cell cycle withdrawal
CDK4/6 inhibitors arrest the cell cycle in G1-phase. They are licenced to treat breast cancer and are also undergoing clinical trials against a range of other tumour types. To facilitate these efforts, it is important to understand why a temporary cell cycle arrest in G1 causes long-lasting effects ...
ORGANISM(S): Homo sapiens (Human) 
2021-12-20 | PXD023435 | Pride
Cdk4/6 cancer replication stress cell cycle senescence 
ProteomicsInhibition of GPX4 enhances CDK4/6 inhibitor activity in breast cancer.
CDK4/6 inhibition is the standard of care for estrogen receptor positive (ER+) breast cancer, although cytostasis is frequently observed, and new treatment strategies that enhance efficacy are required. We performed a genome-wide CRISPR screen to identify genetic determinants of CDK4/6 inhibitors se...
ORGANISM(S): Homo sapiens (Human) 
2023-06-20 | PXD043133 | Pride
Breast cancer Gpx4 Cdk4/6 inhibitor 
Sort   by:  
 Page size